在MDS和AML治疗中,一种代谢优化,非细胞毒性低剂量每周的Decitabine/Venetoclax
David Levitz1, Yogen Saunthararajah2, Kateryna Fedorov1
1Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York.
一种新的每周低剂量西他宾和维尼托克拉克斯疗法对急性髓性白血病 (AML) 和骨髓质综合征 (MDS) 患者有希望,与标准剂量相比,提供更好的治疗持续时间和耐受性.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 与低甲基化剂 (HMA) 结合的Venetoclax (VEN) 是老年急性骨髓性白血病 (AML) 的标准药物,目前正在研究骨髓质疏松综合征 (MDS).
- 标准的HMA/VEN剂量依赖于细胞毒性,通常会导致严重的骨髓抑制,影响正常的血细胞生产.
- 每周低剂量德素 (LDDec) 治疗方案已在髓状瘤恶性瘤中显示出有效性.
研究的目的:
- 为了评估每周一次的低剂量西他 (LDDec) 和venetoclax (VEN) 治疗方案.
- 为了克服与标准HMA/VEN治疗相关的严重骨髓抑制.
- 为了评估老年或虚弱患者对骨髓抑制的耐受性较低的这种治疗方案.
主要方法:
- 对患有AML,MDS或慢性骨髓单细胞白血病的患者进行了回顾性单中心分析.
- 治疗包括每周一次的LDDec/VEN疗法.
- 与接受标准HMA/VEN剂量的队列进行比较.
主要成果:
- 第一线AML和MDS的总体应答率分别为88%和64%,其中LDDec/VEN.
- 在TP53突变患者中,复合完整反应为71%,平均总生存时间为10.7个月.
- LDDec/VEN患者的治疗持续时间较长 (175 vs. 78天;P=0.014) 和倾向于更高的输血独立性 (47% vs. 26%).
结论:
- 每周的LDDec/VEN疗法在髓状瘤恶性瘤中表现出活性.
- 这种方法允许频繁,持续的药物暴露,可能克服标准HMA/VEN的局限性.
- 初步数据表明,治疗持续时间和耐受性有所改善,特别是在脆弱患者群体中.
更多相关视频
14:51Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
相关概念视频
Drugs that Destabilize Microtubules
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers
